For other countries, any question or an interest in distributing OncoDEEP in your country please contact us at email@example.com
OncoDNA, a European leader in targeted cancer therapy, announces today the appointment of Pierre Flamant as Chief Financial Officer.
Jean-Pol Detiffe, Founder and CEO of OncoDNA: “Pierre has gained in-depth and varied financial knowledge thanks to proven experience in international technological SMEs at various stages of growth. He will be able to contribute quickly to the execution of our strategic plan and our international growth.”
Pierre Flamant, “I am thrilled to join OncoDNA at this stage of its development. There is a growing momentum around personalized medicine and OncoDNA’s innovative approach in the fight against cancer. Since successfully raising equity last year and the significant R&D grants received for two of its projects, the company now has the power to scale up and move on to the next level. I look forward to collaborating with the team of experts to achieve it.”
As a graduate of UCL IAG (Louvain School of Management), Pierre Flamant (40) began his career at the audit firm Arthur Andersen in Luxembourg. In 2003, he joined EVS Broadcast Equipment (Euronext Brussels: EVS) to set up the controlling department. In 2005, he moved to XDC, an EVS spin out dedicated to the digital conversion of the cinema industry, assuming financial leadership roles in a fast-changing environment before becoming CFO of dcinex (formerly XDC) in 2012. After the takeover by Ymagis (Euronext Paris: MAGIS) in 2014, he was promoted to CFO for the group.
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.